THU0606 Effect of interleukin-1 antagonists on the quality of life in familial mediterranean fever patients. (12th June 2018)

• Record Type: Journal Article
• Authors: Varan, Ö.; Küçük, H.; Babaoğlu, H.; Atas, N.; Satıs, H.; Bilici Salman, R.; Tufan, A.; Göker, B.; Haznedaroğlu, S.; Öztürk, M.A.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 502
• Page End: 502
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.6495
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Familial Mediterranean Fever (FMF) is characterised by febrile inflammatory painful attacks of peritonitis, pleuritis, arthritis and erzypeloid erythema. Colchicine is the mainstay of treatment in FMF but about%10 patients do not respond well to colchicine. IL-1 antagonists have been shown to be effective in the prevention of attacks in colchicine resistant FMF (crFMF) patients. Herein we investigated effect of these agents on quality of life of crFMF patients. Objectives: to investigate effect of IL-1 antagonists on quality of life of crFMF patients. Methods: Data is derived from Gazi FMF cohort which was established in year 2010. Since then data of patients with FMF who were diagnosed according to the Tel Hashomer criteria were registered. Co-morbidities, detailed attack characteristics, treatments, laboratory parameters and impact of FMF on their life in terms of quality of life were recorded. A retrospective cohort analysis was made from records of patients who were treated with IL-1 inhibitors. SF-36 form was filled before and 3 months after the IL-1 antagonist treatment. Wilcoxon test was used for the analyses and a p value equal or less than 0.05 is considered as statistically significant. Results: there were 41 patients (24 women and 17 men). Anakinra was used in 33 patients and 8 patients received canakimumab. There was a statistically significant reduction in the frequency, severity and the duration of attacks after treatment with IL-1 antagonists (p<0.001, for each). A statistically significant improvement was observed in all domains of SF-36 (figure 1). Conclusions: IL-1 inhibitor therapy reduces frequency, severity and duration of attacks and significantly improves the quality of life of crFMF patients. Disclosure of Interest: None declared